Topical application of ivermectin for the treatment of dermatological conditions/afflictions

A method for treating rosacea, common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatitis or acne necrotica milliaris, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises:

• a thus effective amount of ivermectin;
• an oily phase;
• at least one surfactant-emulsifier selected from the group consisting of polyoxyethylenated fatty acid esters and sorbitan esters;
• a mixture of solvents and/or propenetrating agents for the ivermectin, said solvents and/or propenetrating agents being selected from the group consisting of propylene glycol, ethanol, isopropanol, butanol, N-methyl-2-pyrrolidone, DMSO, polysorbate 80, phenoxyethanol, glyceryl triacetate and oleyl alcohol;
• one or more gelling agents but excluding aluminum magnesium silicate/titanium dioxide/silica;
• and water;
• said composition having lamellar layers of liquid crystals and being chemically stable over a period of 8 weeks;
• said composition being in a form selected from the group consisting of an ointment, a cream, a milk, a pomade, an impregnated pad, a syndet, a towelette, a gel, a spray, a foam, a lotion, a stick, a shampoo, a suspension of microspheres, a suspension of nanospheres, a suspension of lipid vesicles, a suspension of polymeric vesicles, a polymeric patch, and a hydrogel for controlled release.

A method for treating rosacea, comprising topically applying onto the affected skin area of an individual in need of such treatment, a topical pharmaceutical composition which comprises:

• a thus effective amount of ivermectin;
• an oily phase;
• at least one surfactant-emulsifier selected from the group consisting of polyoxyethylenated fatty acid esters and sorbitan esters;
• a mixture of solvents and/or propenetrating agents for the ivermectin, said solvents and/or propenetrating agents being selected from the group consisting of propylene glycol, ethanol, isopropanol, butanol, N-methyl-2-pyrrolidone, DMSO, polysorbate 80, phenoxyethanol, glyceryl triacetate and oleyl alcohol;
• one or more gelling agents selected from the group consisting of carbomers, cellulose derivatives, xanthan gums, guar gums, polyacrylamides, modified starches and aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica;
• and water;
• said composition having lamellar layers of liquid crystals and being chemically stable over a period of 8 weeks;
• said composition being in a form selected from the group consisting of an ointment, a cream, a milk, a pomade, an impregnated pad, a syndet, a towelette, a gel, a spray, a foam, a lotion, a stick, a shampoo, a suspension of microspheres, a suspension of nanospheres, a suspension of lipid vesicles, a suspension of polymeric vesicles, a polymeric patch, and a hydrogel for controlled release.

A topically applicable, stable pharmaceutical composition, said composition comprising:

• an effective amount of ivermectin;
• an oily phase;
• at least one surfactant-emulsifier selected from the group consisting of polyoxyethylenated fatty acid esters and sorbitan esters;
• a mixture of solvents and/or propenetrating agents for the ivermectin, said solvents and/or propenetrating agents being selected from the group consisting of propylene glycol, ethanol, isopropanol, butanol, N-methyl-2-pyrrolidone, DMSO, polysorbate 80, phenoxyethanol, glyceryl triacetate and oleyl alcohol;
• one or more gelling agents but excluding aluminum magnesium silicate/titanium dioxide/silica;
• and water;
• said composition having lamellar layers of liquid crystals and being chemically stable over a period of 8 weeks;
• said composition being in a form selected from the group consisting of an ointment, a cream, a milk, a pomade, an impregnated pad, a syndet, a towelette, a gel, a spray, a foam, a lotion, a stick, a shampoo, a suspension of microspheres, a suspension of nanospheres, a suspension of lipid vesicles, a suspension of polymeric vesicles, a polymeric patch, and a hydrogel for controlled release.